European nations are banning gender affirming care
Robby Starbuck said:
“so called treatments that are so irreversible European nations are even banning or severely restricting them.”
Several European countries have made headlines for pausing or restricting puberty blocker prescriptions for minors, and citing European caution carries weight because these countries have universal healthcare systems with no profit motive and are often seen as progressive on social issues.
A handful of countries, including Sweden, Finland, Denmark and England, have restricted puberty blockers for under-18s outside of research settings while they gather more data: that is a real policy shift, and it is worth being honest about it. But restricting access in one clinical context is not the same as banning a treatment, and it is certainly not the same as Europe repudiating the medical model. Germany, Spain, the Netherlands and many others continue to provide gender-affirming care, including for young people, and none of these policies touch adults at all. The practical cost of framing a partial, ongoing debate as a continent-wide verdict is that trans young people and their parents conclude the science has turned against them, when what has actually happened is a much narrower argument about evidence standards in one area of adolescent medicine. That conclusion stops real people from seeking care that is still available, still supported by major international medical bodies, and still changing lives.
Trans young people and their parents who are given the false impression that the entire medical approach has been repudiated internationally, discouraging them from seeking care that remains available and supported in many countries.